ClinicalTrials.gg
Active, not recruitingNCT06161584Updated Jun 1, 2026

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

An observational study in Geographic Atrophy, sponsored by Apellis Pharmaceuticals, Inc.. Active, not recruiting at 34 sites in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Apellis Pharmaceuticals, Inc. (part of Biogen) · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 45 under way, 5 of them phase 3. Geographic Atrophy · United States.

Planned enrollment
7th of 24
300 · median 138
Started
2023
with 11 others
Observational
24 of 131
7 open now
Primary completion
2027-06
later than 11 of 44 live
Registered
96th of 131
by date
Lead sponsor
8 of 131
Apellis Pharmaceuticals, Inc.

Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 7th largest by planned enrollment of the 24 observational ones that give a count, is one of 12 that started in 2023, is one of 24 observational ones, reaches primary completion later than 11 of the 44 other live ones, and was the 96th registered.

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

Browse Geographic Atrophy studies →

Open to participants now

35 of the 131 studies in Geographic Atrophy with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Geographic Atrophy with a site in United States, or all of them as a file.
02

Study summary

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

03

Conditions studied

  • Geographic Atrophy

Browse trials for

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients residing in the United States who are 60 years or older who have geographic atrophy secondary to age-related macular degeneration

Eligibility criteria

Inclusion Criteria: Eyes are eligible to be included in the study only if all of the following criteria apply. Ocular-specific inclusion criteria apply to the treated eye(s), unless otherwise specified.

  • Eyes that are naive to treatment with pegcetacoplan that are prescribed pegcetacoplan per routine clinical practice according to approved pegcetacoplan prescribing information (ie, the clinical decision to treat with pegcetacoplan must be made before study participation is discussed with the patient)
  • Patient age ≥60 years
  • Visual acuity better than 20/200 on Snellen chart
  • Clinical diagnosis of GA of the macula secondary to AMD in one or both eyes as determined by the investigator using OCT and/or FAF imaging
  • GA lesion meeting the following criteria as determined by the investigator's assessment of Spectralis OCT and/or FAF images at screening:

    1. Nonsubfoveal lesion(s)
    2. GA lesion visualized in its entirety on the macula-centered OCT image and not contiguous with any areas of peripapillary atrophy
    3. Presence of any pattern of hyperautofluorescence in the junctional zone of GA; absence of hyperautofluorescence (ie, pattern = none) exclusionary
  • Adequate clarity of ocular media and adequate pupillary dilation and fixation to permit the collection of good quality images as determined by the investigator
  • Patient willing and able to give and to comply with the study procedures and assessments

Exclusion Criteria: Ocular-specific exclusion criteria apply to the study eye(s) only, unless otherwise specified.

  • GA secondary to a condition other than AMD such as Stargardt disease, cone rod dystrophy, or toxic maculopathies like Plaquenil maculopathy in either eye
  • Active, suspected, or history of intraocular inflammation in either eye at screening or on day 1
  • Any history of or active choroidal neovascularization associated with AMD or any other cause, including any evidence of retinal pigment epithelial tears or rips in SD OCT imaging
  • Presence of an active ocular disease that in the opinion of the investigator compromises or confounds visual function, including but not limited to uveitis and other macular diseases (eg, epiretinal membrane, full thickness macular hole, uncontrolled glaucoma/ocular hypertension). Conditions that in the opinion of the investigator are benign, such as peripheral retina dystrophy, are not exclusionary
  • Any prior treatment with anti-VEGF agents
  • Intraocular surgery (including lens replacement surgery) within 3 months prior to screening
  • History of laser therapy in the macular region
  • Aphakia or absence of the posterior capsule. Note: Yttrium aluminum garnet laser posterior capsulotomy for posterior capsule opacification done at least 60 days prior to screening is not exclusionary.
  • Any ocular condition other than GA secondary to AMD that may require surgery or medical intervention during the study period or, in the opinion of the investigator, could compromise visual function during the study period
  • Any to IVT injection
  • Current ocular or periocular infection in either eye
  • Intravitreal medical device placement
  • Participation in any prior or current systemic experimental treatment within 6 weeks or 5 half lives of the active ingredient (whichever is longer) prior to the start of study treatment or in any other treatments specific to GA. Clinical trials solely involving observation, over-the-counter vitamins, supplements, or diets are not exclusionary
  • Medical or psychiatric conditions that, in the opinion of the investigator, make consistent follow-up unlikely or would make the patient an unsafe study candidate
  • Known to fluorescein sodium for injection or hypersensitivity to pegcetacoplan or any of the in pegcetacoplan solution
  • History or current use of brolucizumab and/or pharmacological treatments that gain approval for the treatment of GA
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • Observation

    Drug: Pegcetacoplan

Interventions

  • Administered intravitreally (IVT) in eyes with geographic atrophy (GA)

    Also known as: Syfovre

06

What researchers measure

Primary outcomes

  1. Incidence of ocular AEs in treated eyes overall and according to physician-directed treatment interval based on US prescribing information

    Time frame: Up to 36 months

  2. Incidence of other events of interest

    Time frame: Up to 36 months

Secondary outcomes

  1. Assess real-world treatment patterns and use of pegcetacoplan considering the proportion of participants with bilateral GA treated with pegcetacoplan in both eyes

    Time frame: Up to 36 months

  2. If only one eye is treated, the criteria for determination of the eye to be treated

    Time frame: Up to 36 months

  3. The treatment interval (mean days between injections) over time

    Time frame: Up to 36 months

  4. The frequency of imaging on treated eyes (color fundus photography, spectral domain optical coherence tomography [SD-OCT], fundus autofluorescence, optical coherence tomography angiography [OCT-A

    Time frame: Up to 36 months

  5. The treatment adherence to planned dosing frequency: the number of injections administered divided by the number of injections planned

    Time frame: Up to 36 months

  6. The duration of persistence on treatment: continuous medication usage until a gap of ≥3 months

    Time frame: Up to 36 months

  7. The treatment discontinuation and/or switching to other agents approved for treatment of GA

    Time frame: Up to 36 months

  8. The management of new-onset exudative age-related macular degeneration (eAMD) events in eyes treated with pegcetacoplan in clinical practice

    Time frame: Up to 36 months

  9. The proportion of treated eyes that develop eAMD that receive anti-vascular endothelial growth factor (VEGF) injections

    Time frame: Up to 36 months

  10. The number of anti-VEGF injections per month from diagnosis of eAMD

    Time frame: Up to 36 months

  11. The proportion of anti-VEGF injections given on same day in the same eye as pegcetacoplan

    Time frame: Up to 36 months

07

Study locations

34 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2023 (actual). Primary completion is estimated for Jun 2027, 45 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2023
First posted
Dec 8, 2023
StartActual
Sep 28, 2023
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06161584
Responsible party
Sponsor
First posted
Dec 8, 2023
Start date
Sep 28, 2023
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jun 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion